Clinical Trials Using Floxuridine
Clinical trials are research studies that involve people. The clinical trials on this list are studying Floxuridine. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Medtronic Pump and Codman Catheter in Delivering Chemotherapy Directly to the Liver in Patients with Metastatic Colorectal Cancer or Cholangiocarcinoma
This phase II trial studies the side effects of a Medtronic pump and Codman catheter when used to deliver chemotherapy directly to the liver in patients with cholangiocarcinoma or colorectal cancer that has spread to other places in the body (metastatic). The Medtronic pump and Codman catheter are devices that are surgically placed in the liver and used to deliver treatment directly to tumor cells which may help to shrink the tumor. Drugs used in chemotherapy, such as floxuridine and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using the Medtronic pump and Codman catheter to deliver chemotherapy may work better in treating patients with colorectal cancer or cholangiocarcinoma.
Location: 7 locations
Mitomycin C or Floxuridine and Leucovorin Calcium during or after Surgery in Treating Patients with Appendiceal, Colon, or Rectal Cancer
This randomized phase II trial studies how well mitomycin C or floxuridine and leucovorin calcium during or after surgery works in treating patients with appendiceal, colon, or rectal cancer. Drugs used in chemotherapy, such as mitomycin C, floxuridine, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether heating a chemotherapy solution and infusing it directly into the abdomen during surgery kills more tumor cells than infusing a chemotherapy solution directly into the abdomen after surgery.
Location: 10 locations
Hepatic Arterial Infusion Using Codman Catheter / Synchromed Pump for the Treatment of Unresectable Colorectal Cancer Liver Metastases or Unresectable Intrahepatic Cholangiocarcinoma
This phase I trial studies the side effects of hepatic arterial infusion (HAI) using the Codman catheter / Synchromed pump in treating patients with colorectal cancer that has spread to the liver (metastases) and cannot be removed by surgery (unresectable) or unresectable intrahepatic cholangiocarcinoma. HAI is a procedure in which chemotherapy drugs are directly delivered to the liver through a pump that is surgically implanted into the liver. This approach can produce higher local concentrations of the infused drug with few systemic side effects. The manufacturer of the main pump device used for HAI terminated production in April 2018. Thus, alternate means of employing HAI need to be devised in order to continue offering this therapy. This trial may help researchers learn about the safety of HAI using a similar pump, the Synchromed II, combined with a Codman vascular catheter.
Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky
mFOLFIRNOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone with Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients with liver-dominant intrahepatic cholangiocarcinoma (ICC) that cannot be removed by surgery (unresectable). Drugs used in chemotherapy regimens, such as mFOLFIRINOX and mFOLFIRI (Oxaliplatin, Irinotecan, Fluorouracil, Folinic acid, Floxuridine) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Delivering chemotherapy via HAI (hepatic arterial infusion) can allow for liver-directed treatment while limiting toxic side effects typically seen with traditional chemotherapy.
Location: OHSU Knight Cancer Institute, Portland, Oregon